NCT03419429

Brief Summary

Modified perforated membrane (MPM) is considered as a modality that could enable participation of periosteal cells and gingival stem cells which could improve the outcomes of guided tissue regeneration more than the use of the traditional occlusive membrane (OM). Simvastatin (SMV) modulates bone formation by increasing the expression of bone morphogenetic protein 2 and angiogenesis. Ethylenediaminetetraacitic acid (EDTA) found to be effective as low ph etchant for smear layer removal and exposing root surface collagen. The investigators compared the clinical and radiographic outcome of SMV gel combined with MPM to SMV gel combined with OM with and without an associated EDTA gel root surface etching for improving bone regeneration in intrabony defects in chronic periodontitis patients. Moreover, evaluation of SMV gingival crevicular fluid (GCF) levels availability for 30 days in cases with and without EDTA root surface etching was performed.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Jan 2016

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2016

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2017

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

January 17, 2018

Completed
19 days until next milestone

First Posted

Study publicly available on registry

February 5, 2018

Completed
Last Updated

February 6, 2018

Status Verified

February 1, 2018

Enrollment Period

1.4 years

First QC Date

January 17, 2018

Last Update Submit

February 5, 2018

Conditions

Keywords

Guided tissue membranesEDTASimvastatin

Outcome Measures

Primary Outcomes (6)

  • Probing pocket depth

    Probing pocket depth was measured from the free gingival margin to the base of the pocket from baseline to 6 months and 9 months

    Baseline to 9 months

  • Clinical attachment level

    Clinical attachment level was measured from the cementoenamel junction to the base of the pocket from baseline to 6 months and 9 months

    Baseline to 9 months

  • Plaque index

    Plaque index was measured from baseline to 6 months and 9 months

    Baseline to 9 months

  • Gingival index

    Gingival index was measured from baseline to 6 months and 9 months

    Baseline to 9 months

  • Linear measurements

    Linear measurements were measured using Digora software from baseline to 6 months and 9 months

    Baseline to 9 months

  • Radiodensitometric measurements

    Bone density was measured using Digora software from baseline to 6 months and 9 months

    Baseline to 9 months

Secondary Outcomes (1)

  • Simvastatin gingival crevicular fluid levels

    Day 1, 7, 14, 21 and 30

Study Arms (4)

Simvastatin/Occlusive membrane

EXPERIMENTAL

open flap procedure, 1.2%simvastatin gel applied and covering the defect with resorbable collagen occlusive membrane .

Drug: SimvastatinDevice: Occlusive membrane

Simvastatin/perforated membrane

EXPERIMENTAL

open flap procedure, 1.2% simvastatin gel and covering the defect with resorbable collagen modified perforated membrane.

Drug: SimvastatinDevice: Modified perforated membrane

EDTA/Simvastatin/Occlusive membrane

EXPERIMENTAL

open flap procedure, 24% EDTA root surface etching,1.2% simvastatin gel and then coverage of the defect with occlusive membrane.

Drug: SimvastatinOther: EDTADevice: Occlusive membrane

EDTA/Simvastatin/perforated membrane

EXPERIMENTAL

open flap procedure, 24% EDTA root surface etching, 1.2% simvastatin gel and then coverage of the defect with modified perforated membrane.

Drug: SimvastatinOther: EDTADevice: Modified perforated membrane

Interventions

Simvastatin is a drug used orally for treatment of hypercholesterolemia. It assists in bone regeneration and has anti-inflammatory effect when applied locally in intrabony defects for periodontal therapy.

EDTA/Simvastatin/Occlusive membraneEDTA/Simvastatin/perforated membraneSimvastatin/Occlusive membraneSimvastatin/perforated membrane
EDTAOTHER

EDTA is a demineralizing agent used for root surface conditioning.

Also known as: Ethylenediaminetetraacitic acid
EDTA/Simvastatin/Occlusive membraneEDTA/Simvastatin/perforated membrane

Occlusive membrane is the traditional collagen resorbable membrane used in guided tissue regeneration.

Also known as: Resorb resodont forte
EDTA/Simvastatin/Occlusive membraneSimvastatin/Occlusive membrane

Modified perforated membrane is the traditional collagen resorbable membrane but modified to be perforated. It is used in guided tissue regeneration

Also known as: Resorb resodont forte
EDTA/Simvastatin/perforated membraneSimvastatin/perforated membrane

Eligibility Criteria

Age30 Years - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Patients were all healthy and free from any systemic disease.
  • No history of antibiotic therapy or periodontal treatment for at least six months preceding the study.
  • Patients were willing and able to return for multiple follow up visits.
  • Periodontal defects with
  • Probing depth \> 5 mm.
  • Clinical attachment loss \>4 mm.
  • Standardized radiographic evidence of interproximal intrabony defect using periapical radiograph.
  • Good level of oral hygiene (plaque and gingival indices score after initial phase therapy should be less than one).

You may not qualify if:

  • Pregnancy, lactation for female patients.
  • Smokers, alcoholics and those receiving any medication that could affect healing of soft tissue and bone as steroids and cyclosporines.
  • History of allergic reaction to the medications used.
  • Vulnerable groups and handicapped.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Chronic Periodontitis

Interventions

SimvastatinEdetic Acid

Condition Hierarchy (Ancestors)

PeriodontitisPeriodontal DiseasesMouth DiseasesStomatognathic DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

LovastatinNaphthalenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsPolycyclic CompoundsEthylenediaminesDiaminesPolyaminesAminesAcetatesAcids, AcyclicCarboxylic Acids

Study Officials

  • Ahmed Y Gamal, Professor

    Faculty of dentistry- Ain Shams University

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate lecturer of oral medicine and periodontology

Study Record Dates

First Submitted

January 17, 2018

First Posted

February 5, 2018

Study Start

January 1, 2016

Primary Completion

June 1, 2017

Study Completion

June 1, 2017

Last Updated

February 6, 2018

Record last verified: 2018-02